Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

(2012) F. Damm et al.   BLOOD

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

(2012) V. Visconte et al.   BLOOD

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

(2012) M. Cazzola et al.   BLOOD

The development and application of small molecule modulators of SF3b as therapeutic agents for cancer

(2012) Thomas R. Webb et al.   DRUG DISCOVERY TODAY

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

(2012) J. Broseus et al.   HAEMATOLOGICA

High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms

(2012) S. Jeromin et al.   HAEMATOLOGICA

Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

(2012) V Visconte et al.   LEUKEMIA

Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up

(2012) Kazuyuki Matsuda et al.   LEUKEMIA RESEARCH

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

(2011) M. M. Patnaik et al.   BLOOD

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

(2011) F Damm et al.   LEUKEMIA

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts

(2011) V Visconte et al.   LEUKEMIA

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

(2011) E. Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

(2009) L. Malcovati et al.   BLOOD

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

(2009) S. Schnittger et al.   HAEMATOLOGICA

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

(2009) J. Flach et al.   HAEMATOLOGICA

Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?

(2008) Douglas Wardrop et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

(2008) A. H. Schmitt-Graeff et al.   HAEMATOLOGICA

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis

(2008) S. Schnittger et al.   HAEMATOLOGICA

Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status

(2008) J. M. Raya et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The Role of JAK2 Mutations in RARS and Other MDS

(2008) E. Hellstrom-Lindberg et al.   Hematology-American Society of Hematology Education Program